N-terminal pro brain natriuretic peptide predicts both all-cause and cardiovascular disease mortality in Japanese hemodialysis patients

What Was Tested

This observational study paper looks at BNP (Nesiritide).

The association between N-terminal pro brain natriuretic peptide (NT-proBNP) level and long-term mortality in Japanese hemodialysis patients has not been fully assessed.

Who Took Part

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

This prospective, multicenter study included 1428 hemodialysis outpatients.

Baseline NT-proBNP levels were measured at the first hemodialysis session of the week and participants were followed for 5 years.

How the Study Was Run

The design is described as multicenter.

More than one site took part, so the participants came from several places.

The methods mention a period of 5 years.

The areas under the curve were calculated from receiver operating characteristic curves.

Groups determined by quartiles of baseline NT-proBNP level were assessed by the Kaplan-Meier method and log-rank test.

What Was Measured

The association between N-terminal pro brain natriuretic peptide (NT-proBNP) level and long-term mortality in Japanese hemodialysis patients has not been fully assessed.

PubMed files the paper under topics including Area Under Curve, Biomarkers, Cardiovascular Diseases, Cause of Death, Japan, Kaplan-Meier Estimate and Natriuretic Peptide, Brain.

The authors tagged it with the keywords All-cause mortality, Cardiovascular disease mortality, Hemodialysis and N-terminal pro brain natriuretic peptide.

What This Means in Plain Language

The paper is a multicenter study of BNP (Nesiritide) over 5 years.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Clinical and experimental nephrology), a journal based in Japan.

More context: the BNP (Nesiritide) compound page, all human trials.